Evidence map›Paper›PMID 27688181›Full record

ArticleEuropean journal of medicinal chemistry2017

Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.

Sudharshan Madapa, Satishkumar Gadhiya, Thomas Kurtzman, Ian L Alberts, Steven Ramsey, Maarten Reith, Wayne W Harding

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Natural Product-Inspired Dopamine Receptor Ligands.Journal of medicinal chemistry · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Sudharshan MadapaDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, USA.
Satishkumar GadhiyaDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, USA; Ph.D. Program in Chemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA.
Thomas KurtzmanPh.D. Program in Chemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA; Ph.D. Program in Biochemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA; Department of Chemistry, Lehman College, The City University of New York, Bronx, NY 10468, USA.
Ian L AlbertsDepartment of Natural Sciences, LaGuardia Community College, City University of New York, New York, NY 11101, USA.
Steven RamseyPh.D. Program in Biochemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA; Department of Chemistry, Lehman College, The City University of New York, Bronx, NY 10468, USA.
Maarten ReithDepartment of Psychiatry, New York University, New York, NY 10016, USA.
Wayne W HardingDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, USA; Ph.D. Program in Chemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA; Ph.D. Program in Biochemistry, CUNY Graduate Center, 365 5th Avenue, New York, NY 10016, USA. Electronic address: whardi@hunter.cuny.edu.
City University of New York · USThe Graduate Center, CUNY · USHunter College · USLaGuardia Community College · USNew York University · US

Funding

Basic and Translational Research Center for Reducing Health DisparitiesG12MD007599 · NIMHD · HUNTER COLLEGE · PI ANGULO, JESUS A · 2012 to 2017
$14.6M
Structure-activity relationship studies on NantenineSC1GM092282 · NIGMS · HUNTER COLLEGE · PI HARDING, WAYNE WESLEY · 2012 to 2015
$1.2M
Solvation Directed Design of Flavonoid Derivatives for Caspase InhibitionSC3GM095417 · NIGMS · HERBERT H. LEHMAN COLLEGE · PI KURTZMAN, THOMAS PHILIP · 2012 to 2020
$948k
NIGMS NIH HHS SC1 GM092282NIGMS NIH HHS SC3 GM095417NIMHD NIH HHS G12 MD007599
6 · The paper itself

Abstract

Tetrahydroprotoberberine alkaloids have shown interesting polypharmacological actions at dopamine receptors and are a unique template from which to mine novel molecules with dual selective actions at D1 and D3 receptors. Such compounds will be valuable to evaluate as anti-cocaine therapeutics. Towards that eventual goal, we engaged an SAR study in which a series of C9 alkoxy analogues of the D1/D2/D3 ligand (-)-stepholidine that possessed or lacked a C12 bromo functionality, were synthesized and evaluated for affinity at dopamine D1, D2 and D3 receptors. We found that the analogues are generally selective for the D1 receptor. Small n-alkoxy substituents (up to 4 carbons in length) were generally well tolerated for high D1 affinity but such groups reduced D3 affinity. In the case of C12 brominated analogues, C9 alkoxylation also had little effect on D1 affinity for the smaller alkoxy groups, but reduced D2 and D3 affinities significantly. C12 bromination tends to increase D1 receptor selectivity. A number of compounds were identified that retain affinity for D1 and D3 receptors but lack D2 receptor affinity. Among them, compound 22a was found to be a selective D1/D3 dual antagonist (Ki = 5.3 and 106 nM at D1 and D3 receptors). Docking studies performed on the analogues at the D3 receptor revealed a number of interactions that are important for affinity including a critical N - Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions between the aryl rings and Phe106 and Phe345. The analogues adopt an orientation in which ring A is located in the orthosteric binding site while the C9 alkoxy substituents attached to ring D project into the secondary binding pocket of the D3 receptor.

Indexed as

AnimalsBerberineBinding SitesCocaine-Related DisordersHumansLigandsMolecular Docking SimulationReceptors, DopamineReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Dopamine D3Structure-Activity RelationshipBerberineLigandsReceptors, DopamineReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Dopamine D3stepholidineD1D3DopamineStepholidineTetrahydroprotoberberineTHPB

Identifiers

PMID27688181
PMCPMC5148686
OpenAlexW2519252136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.